{
  "abstract": "Background and Importance During the process of reconstituting cytotoxic chemotherapies, quality control of the preparation is a crucial step in patient care, both for the efficacy of the preparation and for the safety of patients and healthcare personnel.Aim and Objectives To assess current practices related to the reconstitution and handling of cytotoxic chemotherapies within the Medical Oncology Department of Oran University Hospital (CHU Oran). To estimate the economic impact of residuals from the reconstitution of cytotoxic chemotherapies.Material and Methods Type of study: Descriptive, prospective study conducted from 15 January 2022, to 15 April 2022. Study site: Medical Oncology Department, CHU Oran. Target population: Personnel handling cytotoxic chemotherapy preparations.Results Routes of administration: Infusions and IV boluses were the most recommended, representing 43.48% and 36.96%, respectively. In practice, IV boluses (44.57%) and infusions (40.22%) were the most frequently used. Personnel and training: Most preparations were carried out by untrained biologists (87%), who were not adequately aware of the specific risks associated with cytotoxic drugs. Instances were observed where preparers did not respect prescribed doses – for example, when a dose of 5-FU 609 mg was prescribed, only 600 mg was prepared to avoid opening a new vial. This highlights the importance of recruiting pharmacists to ensure prescription accuracy and compliance with oncologists’ orders Economic impact: The financial losses resulting from the preparation of anticancer drugs amounted to 1,521,890.82 Algerian Dinars (≈ 4.94%) of the total drug consumption cost. Although protocol-based preparation scheduling helped reduce wastage, losses remained significant, mainly due to non-compliance with good preparation practices.Conclusion and Relevance The centralisation of cytotoxic drug preparation, supervised by qualified personnel with appropriate training and pharmacological guidance throughout the reconstitution process, appears to be the most effective means of reducing staff and environmental exposure to these toxic substances. Furthermore, managing chemotherapy residuals (leftovers) can lead to significant cost savings for healthcare institutions.References and/or Acknowledgements 1. French National Authority for Health (HAS). Tools for Securing and Self-Assessment of Medication Administration. 2013.2. Bonan-Hayat, B. Securing the Chemotherapy Circuit in Hospital Settings: Application to the Production of Anticancer Drugs. 3. Committee on the Evolution of Pharmaceutical Care Practices, Québec. Report. 2016.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Faculty of Medecine Pharmacy Departement University Hospitall Establishment Oran Algeria, Algeria, Bir El Djir, Algeria"
      ],
      "name": "N Amara"
    },
    {
      "affiliations": [
        "Faculty of Medecine Eschtablisment Univesity Hospital, Oran, Oran, Algeria"
      ],
      "name": "H Fetati"
    },
    {
      "affiliations": [
        "Faculty of Medecine Eschtablisment Univesity Hospital, Oran, Oran, Algeria"
      ],
      "name": "H Toumi"
    }
  ],
  "title": "5PSQ-149 Safety management of cytotoxic chemotherapy preparation processes and the pharmacoeconomic impact of reconstitution residual",
  "uid": "84c25707-abdd-5d3c-88c2-f6c66744e585"
}